Navigation Links
High-Dose Chemo Fails Against Small Cell Lung Cancers
Date:4/9/2008

Tripled dose was ineffective and toxic, so strategy should be abandoned, study says

WEDNESDAY, April 9 (HealthDay News) -- High-intensity chemotherapy does not improve the survival rate of patients with small cell lung cancer (SCLC), a new Swiss study concludes.

Testing on 140 patients in a randomized trial showed no statistically significant differences in survival rate or tumor size between groups receiving either standard or high doses of chemo over a three-year period. The findings were published online April 8 in the Journal of the National Cancer Institute.

Researchers thought upping the amount of chemotherapy might help the patients live longer because laboratory data had suggested that higher doses kill SCLC cells resistant to standard doses.

"The approach explored in the present trial succeeded in raising the peak dose, total dose and dose intensity of (the chemotherapy drugs) by threefold but has clearly been ineffective and highly toxic," the authors wrote. "As a result, this strategy should be abandoned."

SCLC accounts for almost 13 percent of lung cancer cases in the United States. While many patients initially respond to chemotherapy, most suffer disease recurrence relatively quickly.

The study, lead by Dr. Serge Leyvraz of the University Hospital in Lausanne, Switzerland, compared high-dose and standard-dose chemotherapy using the drug agents: ifosfamide, carboplatin and etoposide (ICE).

The survival rates in the group were similar: 18 percent of the high-dose patients were alive after three years, 19 percent of standard-dose patients survived. Tumor shrinkage was also similar in the two groups: 78 percent among the high-dose recipients and 68 percent in the standard-dose arm.

More information

The National Cancer Institute has more about lung cancer.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, April 8, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
2. High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
3. High-Dose Chemo Helps Beat Rare Brain Cancer
4. Chemotherapy may be culprit for fatigue in breast cancer survivors
5. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
6. To evade chemotherapy, some cancer cells mimic stem cells
7. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
8. PET scans can accurately detect a breast tumors response to chemotherapy
9. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
10. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
11. Medicare modernization act did not change chemotherapy as feared
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: